Your email has been successfully added to our mailing list.

×
0.000288163676968486 -0.000252143217347378 -0.00133275700597936 -0.000972552409768657 0.00154887976370576 0.00226928895612717 0.00118867516749518 0.00334990274475902
Stock impact report

Moderna says its RSV shot is 50% effective after 18 months [CNBC]

Pfizer, Inc. (PFE) 
Last pfizer, inc. earnings: 4/28 06:45 am Check Earnings Report
Company Research Source: CNBC
In their clinical trials, GSK's RSV vaccine Arexvy was 78% effective in preventing severe RSV over a second year and Pfizer' s was 78% effective midway through a second RSV season. Moderna presented the data at a meeting of the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. The drugmaker has previously cautioned against comparing its vaccine to rivals, noting that the trials were not head-to-head and used different case definitions for RSV disease. Shares of Moderna fell roughly 6% in early trading Wednesday. Show less Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for PFE alerts
Opt-in for
PFE alerts

from News Quantified
Opt-in for
PFE alerts

from News Quantified